Recent Updates — AIDX
On September 16, 2026, shareholders of 20/20 Biolabs, Inc. approved an amendment to the Certificate of Incorporation at an adjourned annual meeting, increasing the authorized number of common shares from 50 million to 500 million. The proposal received 3,028,609 votes in favor, with 1,155,607 against and 72,621 abstentions out of a quorum representing 4,256,837 shares. This corporate governance change expands the company's capacity to issue equity for future financing or operational needs. The company operates in the biotechnology industry.
20/20 Biolabs, Inc. received a notification from Nasdaq on September 3, 2026, indicating non-compliance with the $2,500,000 stockholders' equity requirement under Listing Rule 5550(b)(1). The company's Form 10-Q for the period ended June 30, 2026, reported stockholders’ equity of $1,620,700. Nasdaq has granted the company 45 calendar days to submit a plan to regain compliance; if accepted, an extension of up to 180 calendar days may be granted. Failure to comply by January 13, 2027, would disqualify the company from a second compliance period for its previously cited bid price deficiency. The company operates in the biotechnology industry, focusing on laboratory diagnostics and research products.
20/20 Biolabs reported second quarter 2026 financial results with total revenue increasing 36.5% to $0.7 million and gross profit rising 86.6% to $0.3 million, driven by a 47.1% year-over-year increase in OneTest™ revenue to $0.7 million. Gross margin expanded to 41.7% from 30.5%, while the net loss widened to $1.5 million due to operating expenses and non-cash charges. The company strengthened its balance sheet by raising $6.0 million in Series E preferred financing during the first half of 2026 and eliminating all convertible note debt through conversion into preferred stock. Cash reserves grew to $4.5 million as of June 30, 2026. Additionally, the company entered a standstill agreement with Streeterville regarding potential conversions of its Series E shares. The company operates in the healthcare diagnostics industry, developing AI-powered blood tests for early cancer detection.